HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy: Difference between revisions
| [pending revision] | [pending revision] |
| Line 272: | Line 272: | ||
| | | | ||
|- | |- | ||
| | |Hyperdiploid | ||
| | | | ||
| | | | ||
| Line 307: | Line 307: | ||
|<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations | |<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations | ||
|Oncogene | |Oncogene | ||
| | |Common | ||
| | |No | ||
|<span class="blue-text">EXAMPLE:</span> Yes (NCCN) | |<span class="blue-text">EXAMPLE:</span> Yes (NCCN) | ||
|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references). | |<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references). | ||
| Line 315: | Line 315: | ||
<br /> | <br /> | ||
|<span class="blue-text">EXAMPLE:</span> Variable LOF mutations | |<span class="blue-text">EXAMPLE:</span> Variable LOF mutations | ||
|Oncogene | |Oncogene | ||
|<span class="blue-text">EXAMPLE:</span> Common (breast cancer) | |<span class="blue-text">EXAMPLE:</span> Common (breast cancer) | ||
| | |No | ||
| | | | ||
|<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer. | |<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer. | ||
| Line 323: | Line 323: | ||
|''FLT3'' | |''FLT3'' | ||
|<span class="blue-text">EXAMPLE:</span> Activating mutations | |<span class="blue-text">EXAMPLE:</span> Activating mutations | ||
|Tyrosine kinase receptor | |Tyrosine kinase receptor | ||
|<span class="blue-text">EXAMPLE:</span> Common (melanoma) | |<span class="blue-text">EXAMPLE:</span> Common (melanoma) | ||
| | |No | ||
| | | | ||
| | | | ||
| Line 331: | Line 331: | ||
|''PTPN11'' | |''PTPN11'' | ||
| | | | ||
|Protein tyrosine phosphatase | |Protein tyrosine phosphatase | ||
| | | | ||
|No | |||
| | | | ||
| | | | ||
|- | |- | ||
|''CREBBP'' | |''CREBBP'' | ||
| | | | ||
|Histone acetyltransferase | |||
| | | | ||
|No | |||
| | | | ||
| | | | ||
|- | |- | ||
|''WHSC1'' | |''WHSC1'' | ||
| | | | ||
|Histone methyltransferase | |||
| | | | ||
|No | |||
| | | | ||
| | | | ||
|- | |- | ||
|''SUV420H1'' | |''SUV420H1'' | ||
| | | | ||
|Histone methyltransferase | |||
| | | | ||
|No | |||
| | | | ||
| | | | ||
|- | |- | ||
|''SETD2'' | |''SETD2'' | ||
| | | | ||
|Histone methyltransferase | |||
| | | | ||
|No | |||
| | | | ||
| | | | ||
|- | |- | ||
|''EZH2'' | |''EZH2'' | ||
| | | | ||
|Histone methyltransferase | |||
| | | | ||
|No | |||
| | | | ||
| | | | ||